3,5,4′-trimethoxy-trans-stilbene loaded PEG-PE micelles for the treatment of colon cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383-+. doi:10.1053/j.gastro.2018.07.017
   PubMed Web of Science ®Google Scholar
• Merchant SJ, Nanji S, Brennan K, et al. Management of stage III colon cancer in the elderly: practice patterns and outcomes in the general population. Cancer Am Cancer Soc. 2017;123(15):2840–2849.
   Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369. doi:10.6004/jnccn.2018.002129632055
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Chen K, Cheng L, et al. Resveratrol and cancer treatment: updates. Ann N Y Acad Sci. 2017;1403(1):59–69. doi:10.1111/nyas.1346628945938
   PubMed Web of Science ®Google Scholar
• Sinha D, Sarkar N, Biswas J, Bishayee A. Resveratrol for breast cancer prevention and therapy: preclinical evidence and molecular mechanisms. Semin Cancer Biol. 2016;40–41:209–232. doi:10.1016/j.semcancer.2015.11.001
   PubMed Web of Science ®Google Scholar
• Nguyen AV, Martinez M, Stamos MJ, et al. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res. 2009;1:25–37. doi:10.2147/CMAR.S454421188121
   PubMedGoogle Scholar
• Patel KR, Brown VA, Jones DJL, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70(19):7392–7399. doi:10.1158/0008-5472.CAN-10-202720841478
   PubMed Web of Science ®Google Scholar
• San Hipolito-Luengo A, Alcaide A, Ramos-Gonzalez M, et al. Dual effects of resveratrol on cell death and proliferation of colon cancer cells. Nutr Cancer. 2017;69(7):1019–1027. doi:10.1080/01635581.2017.135930928937798
   PubMed Web of Science ®Google Scholar
• Feng M, Zhong LX, Zhan ZY, Huang ZH, Xiong JP. Resveratrol treatment inhibits proliferation of and induces apoptosis in human colon cancer cells. Med Sci Monit. 2016;22:1101–1108. doi:10.12659/MSM.89790527040803
   PubMed Web of Science ®Google Scholar
• Juan ME, Alfaras I, Planas JM. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res. 2012;65(6):584–591. doi:10.1016/j.phrs.2012.03.01022465196
   PubMedGoogle Scholar
• Kapetanovic IM, Muzzio M, Huang ZH, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemoth Pharm. 2011;68(3):593–601. doi:10.1007/s00280-010-1525-4
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv. 2014;11(5):647–659. doi:10.1517/17425247.2014.89058824661109
   PubMed Web of Science ®Google Scholar
• Chabert P, Fougerousse A, Brouillard R. Anti-mitotic properties of resveratrol analog (Z)-3,5,4ʹ-trimethoxystilbene. BioFactors. 2006;27(1–4):37–46. doi:10.1002/biof.552027010417012762
   PubMedGoogle Scholar
• Hsieh TC, Wong C, Bennett DJ, Wu JM. Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin alpha v beta 3. Int J Cancer. 2011;129(11):2732–2743. doi:10.1002/ijc.2593021225623
   PubMed Web of Science ®Google Scholar
• Scherzberg MC, Kiehl A, Zivkovic A, et al. Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action. Toxicol Appl Pharm. 2015;287(1):67–76. doi:10.1016/j.taap.2015.05.020
   PubMed Web of Science ®Google Scholar
• Hu XB, Kang RR, Tang TT, et al. Topical delivery of 3,5,4-trimethoxy-trans-stilbene-loaded microemulsion-based hydrogel for the treatment of osteoarthritis in a rabbit model. Drug Deliv Transl Res. 2019;9(1):357–365. doi:10.1007/s13346-018-00604-z30430453
   PubMed Web of Science ®Google Scholar
• Sawant RR, Torchilin VP. Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol Biol. 2010;624:131–149.20217593
   PubMedGoogle Scholar
• Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv. 2012;19(8):363–370. doi:10.3109/10717544.2012.72447323030458
   PubMed Web of Science ®Google Scholar
• Sawant RR, Torchilin VP. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol. 2010;27(7):232–246. doi:10.3109/09687688.2010.51627620929339
   PubMed Web of Science ®Google Scholar
• Harada M, Ohuchi M, Hayashi T, Kato Y. Prolonged circulation and in vivo efficacy of recombinant human granulocyte colony-stimulating factor encapsulated in polymeric micelles. J Control Release. 2011;156(1):101–108. doi:10.1016/j.jconrel.2011.06.02421723892
   PubMedGoogle Scholar
• Biswas S, Kumari P, Lakhani PM, Ghosh B. Recent advances in polymeric micelles for anti-cancer drug delivery. Eur J Pharm Sci. 2016;83:184–202. doi:10.1016/j.ejps.2015.12.03126747018
   PubMed Web of Science ®Google Scholar
• Li W, Wu J, Zhang J, et al. Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile. Drug Deliv. 2018;25(1):827–837. doi:10.1080/10717544.2018.145576329587545
   PubMed Web of Science ®Google Scholar
• Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6(2):99–104. doi:10.1038/sj.cdd.440047610200555
   PubMed Web of Science ®Google Scholar
• Wang YZ, Fan W, Dai X, et al. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharmaceut. 2014;11(4):1140–1150. doi:10.1021/mp4005904
   PubMed Web of Science ®Google Scholar
• Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273–1289. doi:10.1016/j.addr.2003.12.00415109769
   PubMed Web of Science ®Google Scholar
• Abouzeid AH, Patel NR, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharmaceut. 2014;464(1–2):178–184. doi:10.1016/j.ijpharm.2014.01.009
   PubMed Web of Science ®Google Scholar
• Hu X, Yang FF, Liu CY, Ehrhardt C, Liao YH. In vitro uptake and transport studies of PEG-PLGA polymeric micelles in respiratory epithelial cells. Eur J Pharm Biopharm. 2017;114:29–37. doi:10.1016/j.ejpb.2017.01.00428093351
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhang SH, Kang Y, Huang KQ, Gu ZP, Wu J. Advances in long-circulating drug delivery strategy. Curr Drug Metab. 2018;19(9):750–758. doi:10.2174/138920021966618051115235029749307
   PubMed Web of Science ®Google Scholar
• Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release. 2013;166(2):182–194. doi:10.1016/j.jconrel.2012.12.01323262199
   PubMed Web of Science ®Google Scholar
• Rainbolt EA, Washington KE, Biewer MC, Stefan MC. Recent developments in micellar drug carriers featuring substituted poly(epsilon-caprolactone)s. Polym Chem UK. 2015;6(13):2369–2381. doi:10.1039/C4PY01628A
   Web of Science ®Google Scholar